东方生物(688298)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据东方生物四季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力维持稳定,营业收入加倍下滑,前景暗淡

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力明显恶化,产品市场竞争力明显减弱

  现金流能力有所削弱,现金满足投资能力被严重削弱

  财务数据
    截至2024年第一季度实现净利润-0.70亿元,每股收益-0.33元。

    截至2024年第一季度最新股东权益753682.02万元,未分配利润664532.01万元。

    截至2024年第一季度最新总资产875935.42万元,负债122253.40万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入182,922,481.69820,157,331.67652,171,856.12501,543,883.09
营业总成本286,548,849.541,002,299,363.55718,719,790.87457,566,614.1
营业利润-67,454,742.43-383,834,660.32-44,437,855.4360,731,225.57
利润总额-68,117,242.27-404,226,730.41-46,240,019.259,216,651.82
净利润-69,955,283.74-418,268,830.43-67,266,359.1937,946,328.87
其他综合收益-8,352,902.1114,107,016.6924,878,026.6628,919,674.68
综合收益总额-78,308,185.85-404,161,813.74-42,388,332.5366,866,003.55
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计5,271,199,464.935,896,256,738.146,702,004,059.77,323,188,068.49
非流动资产合计3,488,154,724.53,099,694,412.62,467,981,665.792,388,268,354.31
资产总计8,759,354,189.438,995,951,150.749,169,985,725.499,711,456,422.8
流动负债合计1,145,324,298.221,085,787,283.97847,846,850.71,257,114,231.6
非流动负债合计77,209,725.39360,435,718.74395,091,902.52397,245,312.36
负债合计1,222,534,023.611,446,223,002.711,242,938,753.221,654,359,543.96
归属于母公司股东权益合计7,360,714,853.047,436,071,401.357,779,796,043.047,891,029,258.28
股东权益合计7,536,820,165.827,549,728,148.037,927,046,972.278,057,096,878.84
负债和股东权益合计8,759,354,189.438,995,951,150.749,169,985,725.499,711,456,422.8
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计228,718,943.111,077,595,538.03728,268,484.72506,563,103.93
经营活动现金流出小计440,583,920.022,723,186,068.652,347,943,587.961,693,607,023.38
经营活动产生的现金流量净额-211,864,976.91-1,645,590,530.62-1,619,675,103.24-1,187,043,919.45
投资活动现金流入小计539,083,927.86660,309,652.55537,864,910.81378,582,682.54
投资活动现金流出小计639,815,840.582,778,064,372.83759,675,964.56532,042,816.89
投资活动产生的现金流量净额-100,731,912.72-2,117,754,720.28-221,811,053.75-153,460,134.35
筹资活动现金流入小计105,960,000772,000,000701,000,000500,000,000
筹资活动现金流出小计135,986,504.17722,463,734.63665,677,244.47414,360,990.85
筹资活动产生的现金流量净额-30,026,504.1749,536,265.3735,322,755.5385,639,009.15
汇率变动对现金及现金等价物的影响9,312,629.0785,852,483.4294,542,948.62131,790,944.6
现金及现金等价物净增加额-333,310,764.73-3,627,956,502.11-1,711,620,452.84-1,123,074,100.05
期末现金及现金等价物余额2,595,292,577.442,928,603,342.174,844,939,391.445,433,485,744.23
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润-0.70亿元,每股收益-0.33元。

    截至2024年第一季度最新股东权益753682.02万元,未分配利润664532.01万元。

    截至2024年第一季度最新总资产875935.42万元,负债122253.40万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入182,922,481.69820,157,331.67652,171,856.12501,543,883.09
营业总成本286,548,849.541,002,299,363.55718,719,790.87457,566,614.1
营业利润-67,454,742.43-383,834,660.32-44,437,855.4360,731,225.57
利润总额-68,117,242.27-404,226,730.41-46,240,019.259,216,651.82
净利润-69,955,283.74-418,268,830.43-67,266,359.1937,946,328.87
其他综合收益-8,352,902.1114,107,016.6924,878,026.6628,919,674.68
综合收益总额-78,308,185.85-404,161,813.74-42,388,332.5366,866,003.55
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计5,271,199,464.935,896,256,738.146,702,004,059.77,323,188,068.49
非流动资产合计3,488,154,724.53,099,694,412.62,467,981,665.792,388,268,354.31
资产总计8,759,354,189.438,995,951,150.749,169,985,725.499,711,456,422.8
流动负债合计1,145,324,298.221,085,787,283.97847,846,850.71,257,114,231.6
非流动负债合计77,209,725.39360,435,718.74395,091,902.52397,245,312.36
负债合计1,222,534,023.611,446,223,002.711,242,938,753.221,654,359,543.96
归属于母公司股东权益合计7,360,714,853.047,436,071,401.357,779,796,043.047,891,029,258.28
股东权益合计7,536,820,165.827,549,728,148.037,927,046,972.278,057,096,878.84
负债和股东权益合计8,759,354,189.438,995,951,150.749,169,985,725.499,711,456,422.8
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计228,718,943.111,077,595,538.03728,268,484.72506,563,103.93
经营活动现金流出小计440,583,920.022,723,186,068.652,347,943,587.961,693,607,023.38
经营活动产生的现金流量净额-211,864,976.91-1,645,590,530.62-1,619,675,103.24-1,187,043,919.45
投资活动现金流入小计539,083,927.86660,309,652.55537,864,910.81378,582,682.54
投资活动现金流出小计639,815,840.582,778,064,372.83759,675,964.56532,042,816.89
投资活动产生的现金流量净额-100,731,912.72-2,117,754,720.28-221,811,053.75-153,460,134.35
筹资活动现金流入小计105,960,000772,000,000701,000,000500,000,000
筹资活动现金流出小计135,986,504.17722,463,734.63665,677,244.47414,360,990.85
筹资活动产生的现金流量净额-30,026,504.1749,536,265.3735,322,755.5385,639,009.15
汇率变动对现金及现金等价物的影响9,312,629.0785,852,483.4294,542,948.62131,790,944.6
现金及现金等价物净增加额-333,310,764.73-3,627,956,502.11-1,711,620,452.84-1,123,074,100.05
期末现金及现金等价物余额2,595,292,577.442,928,603,342.174,844,939,391.445,433,485,744.23
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
安吉福浪莱进出口贸易有限公司3931.2019.500.00
Fangs Holdings Limited Liability Company3780.0018.750.00
安吉涌威创业投资合伙企业(有限合伙)2078.5810.310.00
香港中央结算有限公司869.574.3124.63
招商银行股份有限公司-广发价值核心混合型证券投资基金338.981.6898.42
中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金280.921.39138.92
中国工商银行股份有限公司-富国文体健康股票型证券投资基金149.670.74149.67
中国建设银行股份有限公司-招商3年封闭运作瑞利灵活配置混合型证券投资基金111.550.55111.55
兴业银行股份有限公司-富国兴远优选12个月持有期混合型证券投资基金109.720.54109.72
Barclays bank plc96.870.4896.87
  主力控盘
  公司简介
东方生物 所属地域: 浙江省 涉及概念: 抗原检测,猴痘概念,人民币贬值受益,肝炎概念,沪股通,新冠检测,医疗器械概念,流感,融资融券
主营业务: 基因制品、生物制品研究、开发、生产;第二、三类6840体外诊断试剂及第二类6840临床检验分析仪器生产;医用塑料包装材料加工、销售,模具加工、销售;销售本公司产品。(不涉及《外商投资产业指导目录》限制类、禁止类项目)(涉及许可证或专项审批的凭许可证或待审批后经营)(依法须经批准的项目,经相关部门批准后方可开展经营活动)
上市日期: 2020-02-05 每股净资产: 36.51元 每股收益: -0.33元 净利润: -0.67亿元 净利润增长率: -33.82%
营业收入: 1.83亿元 每股现金流: -1.05元 每股公积金: 1.96元 每股未分配利润: 32.96元 总股本: 1.68亿 流通股: 1.68亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心